Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Neurol Neuroimmunol Neuroinflamm
2022 Mar 30;93:. doi: 10.1212/NXI.0000000000001161.
Show Gene links
Show Anatomy links
Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models.
Dietrich M
,
Hecker C
,
Martin E
,
Langui D
,
Gliem M
,
Stankoff B
,
Lubetzki C
,
Gruchot J
,
Göttle P
,
Issberner A
,
Nasiri M
,
Ramseier P
,
Beerli C
,
Tisserand S
,
Beckmann N
,
Shimshek D
,
Petzsch P
,
Akbar D
,
Levkau B
,
Stark H
,
Köhrer K
,
Hartung HP
,
Küry P
,
Meuth SG
,
Bigaud M
,
Zalc B
,
Albrecht P
.
???displayArticle.abstract???
BACKGROUND AND OBJECTIVES: Siponimod is an oral, selective sphingosine-1-phosphate receptor-1/5 modulator approved for treatment of multiple sclerosis.
METHODS: Mouse MRI was used to investigate remyelination in the cuprizone model. We then used a conditional demyelination Xenopus laevis model to assess the dose-response of siponimod on remyelination. In experimental autoimmune encephalomyelitis-optic neuritis (EAEON) in C57Bl/6J mice, we monitored the retinal thickness and the visual acuity using optical coherence tomography and optomotor response. Optic nerve inflammatory infiltrates, demyelination, and microglial and oligodendroglial differentiation were assessed by immunohistochemistry, quantitative real-time PCR, and bulk RNA sequencing.
RESULTS: An increased remyelination was observed in the cuprizone model. Siponimod treatment of demyelinated tadpoles improved remyelination in comparison to control in a bell-shaped dose-response curve. Siponimod in the EAEON model attenuated the clinical score, reduced the retinal degeneration, and improved the visual function after prophylactic and therapeutic treatment, also in a bell-shaped manner. Inflammatory infiltrates and demyelination of the optic nerve were reduced, the latter even after therapeutic treatment, which also shifted microglial differentiation to a promyelinating phenotype.
DISCUSSION: These results confirm the immunomodulatory effects of siponimod and suggest additional regenerative and promyelinating effects, which follow the dynamics of a bell-shaped curve with high being less efficient than low concentrations.
Albrecht,
Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography.
2012, Pubmed
Albrecht,
Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography.
2012,
Pubmed
Albrecht,
Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritis.
2007,
Pubmed
Bachmanov,
Food intake, water intake, and drinking spout side preference of 28 mouse strains.
2002,
Pubmed
Beckmann,
Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945.
2018,
Pubmed
Behrangi,
Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action.
2019,
Pubmed
Bigaud,
Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights.
2021,
Pubmed
Bigaud,
Second generation S1P pathway modulators: research strategies and clinical developments.
2014,
Pubmed
Cruz-Herranz,
Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis.
2019,
Pubmed
Cruz-Herranz,
The APOSTEL recommendations for reporting quantitative optical coherence tomography studies.
2016,
Pubmed
Diem,
Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial-study protocol.
2016,
Pubmed
Dietrich,
Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis.
2020,
Pubmed
Dietrich,
Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model.
2018,
Pubmed
Dietrich,
Whole-body positional manipulators for ocular imaging of anaesthetised mice and rats: a do-it-yourself guide.
2017,
Pubmed
Dietrich,
Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats.
2019,
Pubmed
Dietrich,
Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspects.
2019,
Pubmed
Franklin,
Regenerating CNS myelin - from mechanisms to experimental medicines.
2017,
Pubmed
Gabilondo,
Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis.
2014,
Pubmed
Gentile,
Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.
2016,
Pubmed
Gergely,
The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate.
2012,
Pubmed
Hecker,
Comparison of different optomotor response readouts for visual testing in experimental autoimmune encephalomyelitis-optic neuritis.
2020,
Pubmed
Hundehege,
The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis.
2019,
Pubmed
Jaillard,
Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival.
2005,
Pubmed
Kappos,
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
2018,
Pubmed
Kaya,
Live imaging of targeted cell ablation in Xenopus: a new model to study demyelination and repair.
2012,
Pubmed
,
Xenbase
Knier,
Neutralizing IL-17 protects the optic nerve from autoimmune pathology and prevents retinal nerve fiber layer atrophy during experimental autoimmune encephalomyelitis.
2015,
Pubmed
Larabee,
Loss of Nrf2 exacerbates the visual deficits and optic neuritis elicited by experimental autoimmune encephalomyelitis.
2016,
Pubmed
Lewerenz,
Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro.
2009,
Pubmed
Lubetzki,
Remyelination in multiple sclerosis: from basic science to clinical translation.
2020,
Pubmed
Mannioui,
The Xenopus tadpole: An in vivo model to screen drugs favoring remyelination.
2018,
Pubmed
,
Xenbase
Manogaran,
Retinal pathology in experimental optic neuritis is characterized by retrograde degeneration and gliosis.
2019,
Pubmed
Martin,
Bruton's Tyrosine Kinase Inhibition Promotes Myelin Repair.
2020,
Pubmed
,
Xenbase
McDougald,
SIRT1 and NRF2 Gene Transfer Mediate Distinct Neuroprotective Effects Upon Retinal Ganglion Cell Survival and Function in Experimental Optic Neuritis.
2018,
Pubmed
Miron,
M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination.
2013,
Pubmed
Nystad,
Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model.
2020,
Pubmed
O'Sullivan,
The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.
2016,
Pubmed
Prusky,
Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system.
2004,
Pubmed
Saidha,
Optical coherence tomography reflects brain atrophy in multiple sclerosis: A four-year study.
2015,
Pubmed
Smith,
Calpain inhibition reduces structural and functional impairment of retinal ganglion cells in experimental optic neuritis.
2016,
Pubmed
Starossom,
Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation.
2019,
Pubmed
Tham,
Microglial activation state and lysophospholipid acid receptor expression.
2003,
Pubmed
Vargas,
Update on disease-modifying therapies for multiple sclerosis.
2017,
Pubmed
Ward,
Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury.
2020,
Pubmed
Zhan,
The Cuprizone Model: Dos and Do Nots.
2020,
Pubmed
